Scholars Central

Review articlePublished 21 Jan 2012

GLP 1 and Macrovascular Complications

Authors: Dana Sleiman, Sami T. Azar

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type two diabetes remains to be one of the most challenging chronic diseases affecting 26 million people in the United States. Despite advances in the management of this illness, a large number of diabetics suffer from disease related complications. Heart disease and stroke account for a significant percentage of death in diabetics. Advancing treatment options for diabetics beyond glycemic control and Hba1c levels to prevent macrovascular complications should be the target of our management. GLP1, a member of the pro-glucagon incretin family, and GLP1 analogues seems to have beneficial effects on the macrovascular levels, in addition to their established effect on the glycemic control. This article reviews the potential effect of GLP1 family on the macrovascular complications including cardiovascular, cerebrovascular, and peripheral vascular diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Internal Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternal Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Dana Sleiman”
  • BylineArticles whose byline prints “Sami T. Azar”